Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
1.2.1. Rare Hemophilia Factors Market, by Region, 2020-2030 (USD Million)
1.2.2. Rare Hemophilia Factors Market, by Type, 2020-2030 (USD Million)
1.2.3. Rare Hemophilia Factors Market, by Treatment, 2020-2030 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Rare Hemophilia Factors Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Rare Hemophilia Factors Market Dynamics
3.1. Rare Hemophilia Factors Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Growing adoption and approval of new treatment techniques
3.1.1.2. Increased awareness about rare hemophilia disease
3.1.2. Market Challenges
3.1.2.1. High Cost of Rare Hemophilia treatments
3.1.2.2. Inadequate reimbursement
3.1.3. Market Opportunities
3.1.3.1. Ongoing research & development
3.1.3.2. Use of digital health technologies
Chapter 4. Global Rare Hemophilia Factors Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Rare Hemophilia Factors Market, by Type
5.1. Market Snapshot
5.2. Global Rare Hemophilia Factors Market by Type, Performance – Potential Analysis
5.3. Global Rare Hemophilia Factors Market Estimates & Forecasts by Type 2020-2030 (USD Million)
5.4. Rare Hemophilia Factors Market, Sub-Segment Analysis
5.4.1. Factor I
5.4.2. Factor II
5.4.3. Factor V
5.4.4. Factor VII
5.4.5. Factor X
5.4.6. Factor XI
5.4.7. Factor XIII
Chapter 6. Global Rare Hemophilia Factors Market, by Treatment
6.1. Market Snapshot
6.2. Global Rare Hemophilia Factors Market by Treatment, Performance – Potential Analysis
6.3. Global Rare Hemophilia Factors Market Estimates & Forecasts by Treatment 2020-2030 (USD Million)
6.4. Rare Hemophilia Factors Market, Sub Segment Analysis
6.4.1. Factor Concentrates
6.4.2. Fresh Frozen Plasma
6.4.3. Cryoprecipitate
6.4.4. Others
Chapter 7. Global Rare Hemophilia Factors Market, Regional Analysis
7.1. Top Leading Countries
7.2. Top Emerging Countries
7.3. Rare Hemophilia Factors Market, Regional Market Snapshot
7.4. North America Rare Hemophilia Factors Market
7.4.1. U.S. Rare Hemophilia Factors Market
7.4.1.1. Type breakdown estimates & forecasts, 2020-2030
7.4.1.2. Treatment breakdown estimates & forecasts, 2020-2030
7.4.2. Canada Rare Hemophilia Factors Market
7.5. Europe Rare Hemophilia Factors Market Snapshot
7.5.1. U.K. Rare Hemophilia Factors Market
7.5.2. Germany Rare Hemophilia Factors Market
7.5.3. France Rare Hemophilia Factors Market
7.5.4. Spain Rare Hemophilia Factors Market
7.5.5. Italy Rare Hemophilia Factors Market
7.5.6. Rest of Europe Rare Hemophilia Factors Market
7.6. Asia-Pacific Rare Hemophilia Factors Market Snapshot
7.6.1. China Rare Hemophilia Factors Market
7.6.2. India Rare Hemophilia Factors Market
7.6.3. Japan Rare Hemophilia Factors Market
7.6.4. Australia Rare Hemophilia Factors Market
7.6.5. South Korea Rare Hemophilia Factors Market
7.6.6. Rest of Asia Pacific Rare Hemophilia Factors Market
7.7. Latin America Rare Hemophilia Factors Market Snapshot
7.7.1. Brazil Rare Hemophilia Factors Market
7.7.2. Mexico Rare Hemophilia Factors Market
7.8. Middle East & Africa Rare Hemophilia Factors Market
7.8.1. Saudi Arabia Rare Hemophilia Factors Market
7.8.2. South Africa Rare Hemophilia Factors Market
7.8.3. Rest of Middle East & Africa Rare Hemophilia Factors Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Novo Nordisk A/S
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Biogen Inc.
8.3.3. Bayer Healthcare
8.3.4. Pfizer, Inc.
8.3.5. Shire Plc
8.3.6. Sanofi S.A
8.3.7. CSL Behring
8.3.8. Bio Products Laboratory Ltd.
8.3.9. Eli Lilly and Company
8.3.10. GSK Plc
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
